Stati Uniti - inglese - NLM (National Library of Medicine)

dmg america, llc - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - for the topical application of fluoride in a neutral base to aid in the protection against dental caries. ideal for patients with extensive esthetic restorations and/or intolerance to acidic fluorides, kolorz® neutral foam requires a 4-minute application. shake can thoroughly for at least 30 seconds before each use. hold can completely upside down to dispense. see package insert for dosage information. kolorz® by dmg america instructions for use kolorz sixty second fluoride foam kolorz neutral fluoride foam the first time you dispense from a new bottle, gently lift upward on the nozzle to break the protective shipping tab (thin plastic tab located adjacent to "trigger"). if this tab is not broken, there could be an initial surge of foam from the dispenser. dosage and administration: - shake can vigorously before each use. (fig. 1) - turn can completely upside down to dispense. point can towards fluoride applicator tray and slowly press the nozzle to fill tray. use one press per arch, as foam will expand sl

Stati Uniti - inglese - NLM (National Library of Medicine)

medical products laboratories, inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - indications for the topical application of fluoride to aid in the protection against dental caries. shake can thoroughly for at least 30 seconds before each use. hold can completely upside down to dispense. see package insert for dosage information.

Stati Uniti - inglese - NLM (National Library of Medicine)

medical products laboratories, inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - indications for the topical application of fluoride to aid in the protection against dental caries. shake can thoroughly for at least 30 seconds before each use. hold can completely upside down to dispense. see package insert for dosage information.

Stati Uniti - inglese - NLM (National Library of Medicine)

medical products laboratories, inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - indications for the topical application of fluoride to aid in the protection against dental caries. shake can thoroughly for at least 30 seconds before each use. hold can completely upside down to dispense. see package insert for dosage information.

Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - prucalopride succinate -

Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - prucalopride succinate -

Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - prucalopride succinate -

Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - prucalopride succinate -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

forest herbs research ltd - aniseed powder,pseudowintera colorata -

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

viatris limited - cefaclor monohydrate 26.86 mg/ml equivalent to cefaclor 25 mg/ml - granules for oral suspension - 125 mg/5ml - active: cefaclor monohydrate 26.86 mg/ml equivalent to cefaclor 25 mg/ml excipient: dimeticone erythrosine methylcellulose sodium laurilsulfate starch strawberry flavour 052312 ap0551 sucrose xanthan gum - cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: lower respiratory infections, including pneumonia caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains), and s. pyogenes (group a beta- haemolytic streptococci), m.catarrhalis, acute bronchitis, and acute exacerbations of chronic bronchitis. upper respiratory infections, including pharyngitis and tonsillitis caused by s. pyogenes (group a beta-haemolytic streptococci) and m. catarrhalis. otitis media caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains) staphylococci, and s. pyogenes (group a beta-haemolytic streptococci), and m. catarrhalis. skin and soft-tissue infections caused by staphylococcus aureus (including ?-lactamase producing strains), s. pyogenes (group a beta-haemolytic streptococci) and staphylococcus epidermidis (including ?-lactamase producing strains). urinary tract infections, including pyelonephritis and cystitis caused by e. coli, p, mirabilis, klebsiella sp" and coagulase-negative staphylococci. note: cefaclor has been found to be effective in both acute and chronic urinary tract infections; sinusitis; gonococcal urethritis. skin and skin structure infections caused by staphylococcus aureus and s. pyogenes (group a beta-haemolytic streptococci). sinusitis. gonococcal urethritis, but appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. therapy may be started while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.